Alma Therapeutics

Company Overview

Snapshot

Founded in February 2017 by Oz Cabiri, Alma Therapeutics operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on advancing its drug delivery platform. In February 2026, Alma announced a key collaboration with Universkin to introduce an FDA-listed daily mineral serum SPF 50, marking a significant product development and market entry milestone.

Business overview

Alma Therapeutics is a Health Tech & Life Sciences company developing a novel drug delivery platform, the Mobius Capsule, for the oral administration of complex and biologic molecules. This technology utilizes a microneedle-array approach to enable the oral delivery of therapeutic proteins, peptides, and antibodies that typically require injections due to poor oral bioavailability. The company aims to provide a needle-free alternative to injectable drugs, enhancing the quality of life for patients requiring chronic administration of such medications. Alma Therapeutics operates in the pharmaceutical and drug delivery sectors, targeting global markets with its B2B2C business model.

Strategic signal

In February 2026, Alma, a global leader in energy-based medical and aesthetic technologies, announced a key collaboration with dermatological science brand Universkin to introduce an FDA-listed daily mineral serum SPF 50. This partnership signals Alma's strategic expansion beyond its core drug delivery platform into the broader medical and aesthetic technologies market, leveraging its expertise in advanced delivery systems for new product categories. For investors, this indicates a potential diversification of revenue streams and a validation of Alma's technological capabilities in a competitive market.

Company Intelligence Q&A

What is Alma Therapeutics' core product?

Alma Therapeutics' core product is the Mobius Capsule, a novel drug delivery platform designed for the oral administration of complex and biologic molecules such as peptides, proteins, and antibodies.

What significant collaboration did Alma Therapeutics announce in February 2026?

In February 2026, Alma Therapeutics announced a key collaboration with dermatological science brand Universkin to introduce an FDA-listed daily mineral serum SPF 50, marking a new era in post-procedure skincare.

What was the leadership transition announced by Alma in December 2025?

In December 2025, Alma announced a leadership transition where Lior Dayan was appointed Chairman of Sisram Medical, following eight years of successful leadership as CEO of Alma.

What strategic approach did Alma unveil in April 2026?

In April 2026, Alma unveiled its longevity approach at the Alma Academy, focusing on advancing long-term skin performance as part of its strategy in medical aesthetic solutions.

What problem does Alma Therapeutics aim to solve with its technology?

Alma Therapeutics aims to solve the challenge of poor oral bioavailability for therapeutic proteins and peptides, which currently necessitate administration via injections, by providing a needle-free oral delivery alternative.